Urinary proteomics: fancy gadgetry or a clinically useful diagnostic instrument? The end-user's perspective

Reusz, György

doi:10.1111/tri.13374

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, detection of T-cell mediated rejection is not the only need in kidney allograft surveillance [65]. The kidney transplant may be injured by several different causes that require differing approaches for patient management and are indistinguishable by any other available non-invasive test.…”

Section: Kidney Transplantationmentioning

confidence: 99%

Urinary Peptidomic Biomarkers in Kidney Diseases

Sirolli

Pieroni

Liberato

et al. 2019

IJMS

View full text Add to dashboard Cite

In order to effectively develop personalized medicine for kidney diseases we urgently need to develop highly accurate biomarkers for use in the clinic, since current biomarkers of kidney damage (changes in serum creatinine and/or urine albumin excretion) apply to a later stage of disease, lack accuracy, and are not connected with molecular pathophysiology. Analysis of urine peptide content (urinary peptidomics) has emerged as one of the most attractive areas in disease biomarker discovery. Urinary peptidome analysis allows the detection of short and long-term physiological or pathological changes occurring within the kidney. Urinary peptidomics has been applied extensively for several years now in renal patients, and may greatly improve kidney disease management by supporting earlier and more accurate detection, prognostic assessment, and prediction of response to treatment. It also promises better understanding of kidney disease pathophysiology, and has been proposed as a "liquid biopsy" to discriminate various types of renal disorders. Furthermore, proteins being the major drug targets, peptidome analysis may allow one to evaluate the effects of therapies at the protein signaling pathway level. We here review the most recent findings on urinary peptidomics in the setting of the most common kidney diseases.

show abstract

Section: Kidney Transplantationmentioning

confidence: 99%

Urinary Peptidomic Biomarkers in Kidney Diseases

Sirolli

Pieroni

Liberato

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Including both clinical and subclinical rejection episodes, proteomic profiling by CE‐MS enabled detection of T‐cell mediated tubulointerstitial rejection at an early stage of disease progression. However, differentiation of TCMR from stable kidney function is only one aspect and does not cover the full diagnostic need in kidney allograft surveillance . Becoming aware of this fact, implementation of CE‐MS in kidney allograft surveillance was extended to AMR and its differentiation from TCMR within the international research consortium on biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN).…”

Section: Paving the Way To A Ce‐ms‐based All‐in‐one Differential Diagmentioning

confidence: 99%

Proteomics in Kidney Allograft Transplantation—Application of Molecular Pathway Analysis for Kidney Allograft Disease Phenotypic Biomarker Selection

Marx

Metzger

Olagne

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

There is a need for accurate, robust, non-invasive methods to provide early diagnosis of graft lesions after kidney transplantation. A multitude of proteomic biomarkers for the major kidney allograft disease phenotypes defined by the BANFF classification criteria have been described in literature. None of these biomarkers have been established in the clinic. A key reason for this is the lack of clinical validation which is difficult, as even the gold standard of diagnosis, kidney biopsy, is often ambiguous. The semantic clustering by ReviGO on top of transcriptomic pathway analysis is evaluated to connect histological and transcriptomic kidney allograft disease characteristics with proteomic biomarker qualification. By using public data generated in microarray studies of kidney allograft tissue, biological processes and key molecules specifically associated with the different kidney allograft disease phenotypes are identified. Semantic clustering holds the promise to guide adaptation of proteomic marker panels to molecular pathology. This can support the development of noninvasive tests (e.g. in urine, by capillary electrophoresis mass spectrometry) that simultaneously detect diverse kidney allograft phenotypes with high accuracy and sensitivity.

show abstract

Urinary proteomics for kidney dysfunction: insights and trends

Fenton

2021

Expert Review of Proteomics

View full text Add to dashboard Cite

Urinary proteomics: fancy gadgetry or a clinically useful diagnostic instrument? The end-user's perspective

Cited by 3 publications

References 17 publications

Urinary Peptidomic Biomarkers in Kidney Diseases

Urinary Peptidomic Biomarkers in Kidney Diseases

Proteomics in Kidney Allograft Transplantation—Application of Molecular Pathway Analysis for Kidney Allograft Disease Phenotypic Biomarker Selection

Urinary proteomics for kidney dysfunction: insights and trends

Contact Info

Product

Resources

About